Exodus Point Capital Management, LP Erasca, Inc. Transaction History

Exodus Point Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.79 - $2.63 $1.68 Million - $2.46 Million	936,240 Added 375.22%	1,185,758 $2.8 Million
Q1 2024 May 14, 2024	BUY	$1.67 - $2.55 $214,805 - $327,996	128,626 Added 106.4%	249,518 $514,000
Q3 2023 Nov 09, 2023	BUY	$1.97 - $2.91 $67,779 - $100,121	34,406 Added 39.78%	120,892 $238,000
Q2 2023 Aug 10, 2023	BUY	$2.57 - $3.3 $222,269 - $285,403	86,486 New	86,486 $239,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.